Kestra Medical Technologies Q4 Earnings Call Highlights
Kestra Medical Technologies (NASDAQ:KMTS) reported a Q4 GAAP net loss of $38.8 million and adjusted EBITDA loss of $26.7 million. CFO Vaseem Mahboob said gross margin should rise steadily and reiterated confidence in gross margins above 70% over the next few years. The company guided FY2027 revenue to $137 million, up 44% from FY2026, and added a $200 million term loan facility.
How this was made
The 30-second read
Why it matters
The article’s key trading inputs are FY2027 revenue guidance (+44% YoY), gross margin confidence (above 70% over the next few years), and a new non-dilutive $200M term loan facility that increases liquidity and reduces near-term financing risk.
Market read
Guidance and margin trajectory can drive valuation expectations, while the term loan and liquidity figures inform balance-sheet risk and the ability to keep investing through FY2027.
What to watch
Operating expenses excluding SBC rose sharply year over year, and adjusted EBITDA loss widened, so margin progress may depend on continued cost discipline and payer mix improvements.
Background
Kestra is a commercial-stage wearable cardioverter defibrillator and digital health company, with ASSURE as its core product and a direct-to-cardiology sales expansion strategy.
Ticker impact
Kestra guided FY2027 revenue to $137M, 44% growth, and reiterated gross margin above 70% over the next few years on the Q4 call.
Likely supportive for the stock on expectation of accelerating growth and improving margins, tempered by continued cash burn and sizable operating expense growth.
The article includes explicit FY2027 revenue guidance, gross margin targets, and a new $200M term loan with $75M funded at closing, all of which can re-rate expectations. However, it is a call highlights recap rather than a full earnings release, and it does not provide consensus comparisons or actual share price reaction.
Market effects
Could modestly improve sentiment toward wearable cardiac device and digital health commercialization models if investors view margin expansion as credible.
No clear regional read-through beyond US healthcare payer and provider adoption.
Limited, as the guidance and commercialization discussion appears US-focused.
Counterpoint
Revenue growth and margin targets may be optimistic if sales territory expansion and representative ramp do not translate into sustained in-network mix and revenue per fit.
Key entities
- companyKestra Medical Technologies
NASDAQ-listed wearable cardioverter defibrillator and digital health company providing Q4 highlights and FY2027 guidance.
- lenderPharmakon
Counterparty to Kestra’s new $200M term loan facility, with $75M funded at closing.
- productASSURE WCD
Kestra’s wearable cardioverter defibrillator used to protect patients at elevated risk of sudden cardiac arrest.
- clinical programACE-PAS study
Real-world prospective study with 21,000+ enrolled patients, cited as evidence supporting ASSURE.
